keyword
MENU ▼
Read by QxMD icon Read
search

Vulvar cancer

keyword
https://www.readbyqxmd.com/read/28424278/detection-of-hpv-subtypes-by-mass-spectrometry-in-ffpe-tissue-specimens-a-reliable-tool-for-routine-diagnostics
#1
Mark Kriegsmann, Petra Wandernoth, Katharina Lisenko, Rita Casadonte, Rémi Longuespée, Norbert Arens, Jörg Kriegsmann
AIMS: Human papilloma virus (HPV) infection is a causative agent for approximately 5% of all new cancer cases in humans. The virus is detected in cervical, anal, vaginal, penile, vulvar and head and neck cancers and has prognostic implications. Thus, test systems are required to detect high-risk but also low-risk HPV subtypes with high specificity and sensitivity in a time-effective and cost-effective manner. In the present study we developed a new mass spectrometry (MS)-based test system for the detection of HPV infections in formalin-fixed paraffin-embedded (FFPE) tissue samples...
May 2017: Journal of Clinical Pathology
https://www.readbyqxmd.com/read/28418164/molecular-subtyping-of-mammary-like-adenocarcinoma-of-the-vulva-shows-molecular-similarity-to-breast-carcinomas
#2
Basile Tessier-Cloutier, Karama Asleh-Aburaya, Varsha Shah, W Glenn McCluggage, Anna Tinker, C Blake Gilks
AIMS: Mammary-like adenocarcinoma (MLA) of the vulva is thought to be derived from vulvar mammary-like glands. We characterized a series of MLA using an immunohistochemical algorithm that identifies the major molecular subtypes of breast cancer. METHODS AND RESULTS: Seven cases of vulval MLA were stained for ER, PR, HER2, Ki-67, EGFR, CK5, nestin and INPP4b. 17 cases of vulval extramammary Paget disease (EMPD), 7 with invasion, were studied for comparison. The median age of patients with MLA was 72 years...
April 18, 2017: Histopathology
https://www.readbyqxmd.com/read/28409179/vulva-cancer-in-ghana-review-of-a-hospital-based-data
#3
Mary Ann Dadzie, Charles A Aidoo, Verna Vanderpuye
•Seventy- 5% of vulvar cancer cases present with advance disease.•Definitive radiotherapy/chemoradiation is the main stay of treatment.•One third of patients default treatment.•Five year survival following radiotherapy was 36.7%.
May 2017: Gynecologic Oncology Reports
https://www.readbyqxmd.com/read/28400857/estimation-of-the-overall-burden-of-cancers-precancerous-lesions-and-genital-warts-attributable-to-9-valent-hpv-vaccine-types-in-women-and-men-in-europe
#4
Susanne Hartwig, Jean Lacau St Guily, Géraldine Dominiak-Felden, Laia Alemany, Silvia de Sanjosé
BACKGROUND: In addition to cervical cancer, human papillomavirus (HPV) is responsible for a significant proportion of cancers and precancerous lesions of the vulva, vagina, anus, penis, head and neck, as well as genital warts. We estimated the annual number of new cases of these diseases attributable to 9-valent HPV vaccine types in women and men in Europe. METHODS: The annual number of new cancers of the cervix, vulva, vagina, anus, penis, and selected head and neck sites in the population of the European Medicines Agency territory was estimated based on age-specific incidence rates extracted from Cancer Incidence in 5 Continents, Volume X and Eurostat population data for 2015...
2017: Infectious Agents and Cancer
https://www.readbyqxmd.com/read/28399034/sentinel-lymphadenectomy-in-vulvar-cancer-using-near-infrared-fluorescence-from-indocyanine-green-compared-with-technetium-99m-nanocolloid
#5
Philipp Soergel, Hermann Hertel, Anna Kaarina Nacke, Rüdiger Klapdor, Thorsten Derlin, Peter Hillemanns
OBJECTIVE: Nowadays, sentinel diagnostic is performed using technetium 99m (Tc) nanocolloid as a radioactive marker and sometimes patent blue. In the last years, indocyanine green has been evaluated for sentinel diagnostic in different tumor entities. Indocyanine green is a fluorescent molecule that emits a light signal in the near-infrared band after excitation. Our study aimed to evaluate indocyanine green compared with the criterion-standard Tc-nanocolloid. METHODS: We included patients with primary, unifocal vulvar cancer of less than 4 cm with clinically node-negative groins in this prospective trial...
April 8, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28399033/european-society-of-gynaecological-oncology-guidelines-for-the-management-of-patients-with-vulvar-cancer
#6
Maaike H M Oonk, François Planchamp, Peter Baldwin, Mariusz Bidzinski, Mats Brännström, Fabio Landoni, Sven Mahner, Umesh Mahantshetty, Mansoor Mirza, Cordula Petersen, Denis Querleu, Sigrid Regauer, Lukas Rob, Roman Rouzier, Elena Ulrikh, Jacobus van der Velden, Ignace Vergote, Linn Woelber, Ate G J van der Zee
OBJECTIVE: The aim of this study was to develop clinically relevant and evidence-based guidelines as part of European Society of Gynaecological Oncology's mission to improve the quality of care for women with gynecologic cancers across Europe. METHODS: The European Society of Gynaecological Oncology Council nominated an international development group made of practicing clinicians who provide care to patients with vulvar cancer and have demonstrated leadership and interest in the management of patients with vulvar cancer (18 experts across Europe)...
April 8, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28398023/clinical-profile-of-women-with-vva-who-are-not-candidates-for-local-vaginal-oestrogen-therapy
#7
Rossella E Nappi, Filippo Murina, Giuseppina Perrone, Paola Villa, Nicoletta Biglia
Vulvar and vaginal atrophy (VVA) is a chronic medical condition in postmenopausal women, which is predominantly due to a permanent cessation of ovarian oestrogen production. Current available treatment options for VVA are over-the-counter (OTC) symptomatic relief products or local oestrogen therapy (LET) aiming to treat this underlying atrophic condition. Recent surveys indicated that these products decrease sexual spontaneity, are messy and indiscrete. Ospemifene is an oral daily drug, which has proven to treat vaginal dryness and dyspareunia effectively...
April 10, 2017: Minerva Ginecologica
https://www.readbyqxmd.com/read/28377483/vulvar-squamous-cell-carcinoma-vscc-as-two-diseases-hpv-status-identifies-distinct-mutational-profiles-including-oncogenic-fibroblast-growth-factor-receptor-3
#8
Johanne I Weberpals, Bryan Lo, Marc M Duciaume, Johanna N Spaans, Aisling A Clancy, Jim Dimitroulakos, Glenwood D Goss, Harman S Sekhon
PURPOSE: Patients with advanced or recurrent invasive vulvar squamous cell carcinoma (VSCC) have limited treatment options and a grave prognosis. Understanding the genomic landscape may facilitate the identification of new therapies and improve clinical outcomes. EXPERIMENTAL DESIGN: A retrospective chart review and molecular analysis of patients with VSCC from 2000-2016 was performed at the Ottawa Hospital Research Institute. The presence of oncogenic HPV was determined by nested PCR and amplified DNA was sequenced using the Ion AmpliSeq Cancer Hotspot v2 Panel...
April 4, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28356187/vulvar-carcinoma-in-norway-a-50-year-perspective-on-trends-in-incidence-treatment-and-survival
#9
Christin Julia Meltzer-Gunnes, Milada Cvancarova Småstuen, Gunnar Balle Kristensen, Claes Göran Tropé, Agnes Kathrine Lie, Ingvild Vistad
OBJECTIVE: To explore trends in vulvar squamous cell carcinoma (SCC) incidence, age and stage at diagnosis, treatment and survival in Norway from 1961 to 2010. METHODS: From 1961 to 2010, 2233 cases of vulvar SCC were extracted from the Cancer Registry of Norway. Data on age at diagnosis, tumor morphology, stage of the disease and treatment were analyzed. Age-standardized incidence rates, adjusted to the Norwegian standard population, were computed. Relative survival was calculated as a ratio of the observed survival in the study population over the expected survival in the background population...
March 26, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28351815/neoadjuvant-and-definitive-chemotherapy-or-chemoradiation-for-stage-iii-and-iv-vulvar-cancer-a-pooled-reanalysis
#10
Dirk Michael Forner, Peter Mallmann
OBJECTIVES AND METHODS: A number of publications study the treatment of advanced vulvar cancer by neoadjuvant or definitive chemotherapy (CT) or chemoradiation (CRT); however, the reported survival rates vary widely. In a pooled reanalysis of the published data, we studied the factors influencing patients' survival. RESULTS: We included 97 patients with stage III and IV vulvar cancer of publications in our study. In the pooled reanalysis we found that neoadjuvant therapy plus surgery lead to significantly better 5YSR (73%) than definitive CRT (43%) alone...
May 2017: European Journal of Obstetrics, Gynecology, and Reproductive Biology
https://www.readbyqxmd.com/read/28346275/committee-opinion-no-704-human-papillomavirus-vaccination
#11
(no author information available yet)
Human papillomavirus (HPV) is associated with anogenital cancer (including cervical, vaginal, vulvar, penile, and anal), oropharyngeal cancer, and genital warts. The HPV vaccination significantly reduces the incidence of anogenital cancer and genital warts. Despite the benefits of HPV vaccines, only 41.9% of girls in the recommended age group, and only 28.1% of males in the recommended age group have received all recommended doses. Compared with many other countries, HPV vaccination rates in the United States are unacceptably low...
March 24, 2017: Obstetrics and Gynecology
https://www.readbyqxmd.com/read/28333840/primary-versus-preoperative-radiation-for-locally-advanced-vulvar-cancer
#12
Divya Natesan, Julian C Hong, Jonathan Foote, Julie A Sosa, Laura Havrilesky, Junzo Chino
OBJECTIVES: The objective of this study was to evaluate patterns of care and the survival impact of primary radiation and preoperative radiation therapy with surgery in women with locally advanced vulvar cancer using a large national cohort. METHODS AND MATERIALS: Women with vulvar cancer, diagnosed from 2004 to 2012, who received primary or preoperative radiation therapy were identified in the National Cancer Database. Patient characteristics, such as age, race, American Joint Committee on Cancer stage, and comorbidity score, were compared between those that received primary radiation only and those that received preoperative radiation with surgery using the χ, Fisher exact, and Mann-Whitney tests as appropriate...
March 23, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28296310/a-novel-arc-geometry-setting-for-pelvic-radiotherapy-with-extensive-nodal-involvement
#13
Maija Rossi, Eeva Boman, Tanja Skyttä, Mika Kapanen
The aim of this study was to find optimal planning approach for large planning targets with complicated geometry requiring wide field openings. The study presents a novel approach for arc geometry design for pelvic targets with extensive nodal involvement. A total of 15 patients with anorectal carcinoma or vulvar cancer were selected retrospectively. For each patient, one seven-field IMRT plan and three VMAT plans were calculated: one with two 360° arcs with no limitations for the field size (VMATw); one with two asymmetrically field-size-restricted 360° arcs (VMATr); and the proposed novel approach which consisted of one 360° arc with the field size restricted to the central PTV, and another arc divided into two 180° arcs, restricting the field sizes with the focus on the lymph nodes...
July 2016: Journal of Applied Clinical Medical Physics
https://www.readbyqxmd.com/read/28284768/vulvar-cancer-in-tunisia-epidemiological-and-clinicopathological-features-multicentric-study
#14
Mehdi Kehila, Souad Harabi, Raoudha Mhiri, Omar Touhami, Hassine Saber Abouda, Abdeljalil Khlifi, Mohamed Hsairi, Dalenda Chelli, Mohamed Derbel, Sahbi Kebaili, Nadia Boujelbane, Kais Chaabene, Mohamed Badis Chanoufi
OBJECTIVE: To describe for the first time the epidemiologic and clinico-pathologic characteristics of vulvar cancer in Tunisia. DESIGN: Two parts are distinguished in this study: Part1: Multicentric retrospective study about the characteristics of all cancer cases diagnosed during a 17-years period (January 1998-December 2014) in three departments of Gynecology and Obstetrics: one in south Tunisia and two in the capital. Part 2: To determine the Incidence trend of invasive vulvar cancer in North Tunisia 1994-2009, on the basis of North Cancer Registry of Tunisia...
March 8, 2017: Journal of the Egyptian National Cancer Institute
https://www.readbyqxmd.com/read/28275696/surgical-management-of-squamous-cell-vulvar-cancer-without-clitoris-urethra-or-anus-involvement
#15
REVIEW
Alpaslan Kaban, Işık Kaban, Selim Afşar
Vulvar cancers, which constitute 5% of all gynecologic cancers, are the fourth most common female genital cancers, preceded by uterine, ovarian and cervical cancers. The treatment methods employed for vulvar cancers have changed over the years, with previously applied radical surgical approaches, such as en bloc resection, being gradually suspended in favor of treatment approaches that require dissection of less tissue. While the removal of less tissue, which today's approaches have focused on, prevents morbidity, this method seems to result in higher risks of recurrence...
May 2017: Gynecologic Oncology Reports
https://www.readbyqxmd.com/read/28272287/risk-factors-and-outcomes-of-de-novo-cancers-excluding-nonmelanoma-skin-cancer-after-liver-transplantation-for-primary-sclerosing-cholangitis
#16
Mohamad A Mouchli, Siddharth Singh, Edward V Loftus, Lisa Boardman, Jayant Talwalkar, Charles B Rosen, Julie K Heimbach, Russell H Wiesner, Bashar Hasan, John J Poterucha, Kymberly D Watt
BACKGROUND: Patients with primary sclerosing cholangitis (PSC) may be at higher of risk of malignancy after liver transplantation (LT) compared to other LT recipients. We aimed to determine the cumulative incidence of/risk factors for and long-term cancer-related mortality in patients with PSC after LT. METHODS: All adult patients who underwent LT for PSC without cholangiocarcinoma from 1984-2012, with follow-up through June 2015. We estimated cumulative incidence, risk factors and mortality from de novo malignancies after LT RESULTS: 293 patients were identified (mean age, 47±12 years; 63...
March 8, 2017: Transplantation
https://www.readbyqxmd.com/read/28267861/periodic-screening-pelvic-examination-evidence-report-and-systematic-review-for-the-us-preventive-services-task-force
#17
REVIEW
Janelle M Guirguis-Blake, Jillian T Henderson, Leslie A Perdue
Importance: Recent changes in the periodicity of cervical cancer screening have led to questions about the role of screening pelvic examinations among asymptomatic women. Objective: To systematically review literature on health benefits, accuracy, and harms of the screening pelvic examination for gynecologic conditions for the US Preventive Services Task Force (USPSTF). Data Sources: MEDLINE, PubMed, and Cochrane Central Register of Controlled Trials for relevant English-language studies published through January 13, 2016, with surveillance through August 3, 2016...
March 7, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28267367/systematic-indirect-comparison-of-ospemifene-versus-local-estrogens-for-vulvar-and-vaginal-atrophy
#18
N Bruyniks, N Biglia, S Palacios, A O Mueck
In the absence of a direct head-to-head study, we performed an indirect historical comparison of ospemifene 60 mg (Senshio(®)) vs. local vaginal estrogens in moderate or severe vulvar and vaginal atrophy (VVA). A literature search was carried out of clinical efficacy/safety trials of local vaginal estrogens in VVA approved in Europe. For efficacy comparison, studies had to be placebo-controlled and of 12 weeks' duration. For safety comparison, studies had to be ≥40 weeks' duration. Efficacy endpoints were the difference between active and placebo in change from baseline to week 12 for symptoms, vaginal pH, and maturation value (MV)...
March 7, 2017: Climacteric: the Journal of the International Menopause Society
https://www.readbyqxmd.com/read/28262516/brachytherapy-as-part-of-the-conservative-treatment-for-primary-and-recurrent-vulvar-carcinoma
#19
P Castelnau-Marchand, A Escande, R Mazeron, E Bentivegna, A Cavalcanti, S Gouy, C Baratiny, P Maroun, P Morice, C Haie-Meder, C Chargari
PURPOSE: There are only scarce data on the place of brachytherapy (BT) for treatment of vulvar carcinoma. Our institutional experience of interstitial BT for vulvar carcinoma patients is reported. METHODS AND MATERIALS: Clinical records of patients receiving low-dose-rate or pulsed-dose-rate BT as part of the primary treatment for primary/recurrent vulvar squamous cell carcinoma or as part of postoperative treatment between 2000 and 2015 were included. Patients, tumors, and treatment characteristics as well as clinical outcome were examined...
March 2, 2017: Brachytherapy
https://www.readbyqxmd.com/read/28245440/human-papillomavirus-and-the-development-of-different-cancers
#20
REVIEW
Ge Gao, David I Smith
Human papillomaviruses (HPV) are responsible for the development of almost all cervical cancers. HPV is also found in 85% of anal cancer and in 50% of penile, vulvar, and vaginal cancers, and they are increasingly found in a subset of head and neck cancers, i.e., oropharyngeal squamous cell carcinomas (OPSCC). The model for how HPV causes cancer is derived from several decades of study on cervical cancer, and it is just presumed that this model is not only completely valid for cervical cancer but for all other HPV-driven cancers as well...
2016: Cytogenetic and Genome Research
keyword
keyword
2540
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"